[Isolation and gene modification of amniotic fluid derived progenitor cells]

Area of Science:

• Stem Cell Biology
• Gene Therapy
• Hematology

Background:

• Hemophilia B is a genetic bleeding disorder caused by deficiency in coagulation factor IX (FIX).
• Gene therapy offers a potential treatment, but requires safe and effective delivery vehicles.
• Human amniotic fluid-derived progenitor cells (hAFPCs) are a promising cell source due to their accessibility and multipotency.

Purpose of the Study:

• To establish a method for isolating and culturing hAFPCs.
• To genetically engineer hAFPCs to secrete functional human coagulation factor IX (hFIX).
• To evaluate the potential of these engineered cells for prenatal treatment of hemophilia B.

Main Methods:

• Manual isolation of hAFPCs from amniotic fluid based on attachment to gelatin-coated dishes.
• Lentiviral vector-mediated transfection of hAFPCs with hFIX cDNA.
• Quantification of secreted hFIX protein concentration and activity using ELISA and clotting assays.
• Characterization of hAFPCs using immunocytochemistry and quantitative PCR for stem cell markers and pluripotency genes (SSEA4, TRA1-60, NANOG, OCT4, SOX2).

Main Results:

• Isolated hAFPCs exhibited fibroblastoid morphology and expressed key stem cell markers (SSEA4, TRA1-60) and pluripotency genes (NANOG, OCT4, SOX2).
• Transfected hAFPCs successfully produced and secreted functional hFIX into the culture medium.
• Secreted hFIX levels reached a plateau, with stable clotting activity correlating with hFIX concentration.
• The doubling time for cultured hAFPCs was determined to be 39.05 hours.

Conclusions:

• A reliable method for isolating and culturing hAFPCs was established.
• Genetically engineered hAFPCs can stably produce and secrete functional hFIX in vitro.
• Engineered hAFPCs represent a potential cell-based therapy for prenatal treatment of hemophilia B.